Regular and Young Investigator Award Abstracts

492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers

David M. O’Malley, Sylvia Lee, Amanda Psyrri et al. · 2021 · 36 citations · Full text

Pharmacy, Immunology, Oncology +17

421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT

Mark Linch, Zsuzsanna Pápai, István Takács et al. · 2021 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1457 Visium HD enables spatially resolved, single-cell scale resolution mapping of FFPE human breast cancer tissue

Monica Nagendran, Jerald Sapida, Joey Arthur et al. · 2023 · 35 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

Georgina V. Long, Reinhard Dummer, Douglas B. Johnson et al. · 2020 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Mohammed Milhem, Yousef Zakharia, Diwakar Davar et al. · 2020 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17